CA3196286C - Dihydrate de dichlorhydrate de 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphtalene-1-sulfonamide cristallin - Google Patents

Dihydrate de dichlorhydrate de 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphtalene-1-sulfonamide cristallin

Info

Publication number
CA3196286C
CA3196286C CA3196286A CA3196286A CA3196286C CA 3196286 C CA3196286 C CA 3196286C CA 3196286 A CA3196286 A CA 3196286A CA 3196286 A CA3196286 A CA 3196286A CA 3196286 C CA3196286 C CA 3196286C
Authority
CA
Canada
Prior art keywords
compound
disease
inhibitor
cancer
determined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3196286A
Other languages
English (en)
Other versions
CA3196286A1 (fr
Inventor
Adam Galan
Ritu LAL
Wendy Luo
Original Assignee
GEn1E Lifesciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GEn1E Lifesciences Inc filed Critical GEn1E Lifesciences Inc
Priority claimed from PCT/US2021/055950 external-priority patent/WO2022093610A1/fr
Publication of CA3196286A1 publication Critical patent/CA3196286A1/fr
Application granted granted Critical
Publication of CA3196286C publication Critical patent/CA3196286C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne un dihydrate de dichlorhydrate 5-(diméthylamino)-N-(4-(morpholinométhyl)phényl)naphtalène-1-sulfonamide cristallin, des procédés de préparation du sel cristallin, des compositions pharmaceutiques contenant le sel cristallin et des procédés de traitement utilisant le sel cristallin.
CA3196286A 2020-10-29 2021-10-21 Dihydrate de dichlorhydrate de 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphtalene-1-sulfonamide cristallin Active CA3196286C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106991P 2020-10-29 2020-10-29
US63/106,991 2020-10-29
PCT/US2021/055950 WO2022093610A1 (fr) 2020-10-29 2021-10-21 Dihydrate de dichlorhydrate de 5-(diméthylamino)-n-(4-(morpholinométhyl)phényl)naphtalène-1-sulfonamide cristallin

Publications (2)

Publication Number Publication Date
CA3196286A1 CA3196286A1 (fr) 2022-05-05
CA3196286C true CA3196286C (fr) 2026-03-10

Family

ID=

Similar Documents

Publication Publication Date Title
US11926635B2 (en) P38α mitogen-activated protein kinase inhibitors
US12331024B2 (en) Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors
US20250333387A1 (en) Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt
US20250243154A1 (en) Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate
CA3196286C (fr) Dihydrate de dichlorhydrate de 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphtalene-1-sulfonamide cristallin
US12404259B2 (en) Inhibitors of extracellular signal-regulated kinase
HK40096869A (zh) 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物
HK40104521A (zh) 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂